FDA Approves Teva's Igalmi Sublingual Film for At-Home Use
Teva Pharmaceutical Industries (TEVA) has received U.S. FDA approval to expand the administration of its drug, Igalmi (dexmedetomidine), to include at-home use. The sublingual film is indicated for treating agitation associated with schizophrenia, bipolar disorder, or schizoaffective disorder. While Igalmi was previously approved in 2022 for these same indications, this new authorization allows patients to manage symptoms in a home setting rather than being restricted to clinical environments. This expansion potentially increases the drug's accessibility and market reach among patients requiring outpatient management of psychiatric agitation.